CDK4/6i are synergistic in combination with [ 177 Lu] Lu-DOTATATE and [ 177 Lu]Lu-PSMA (EANM 2026) - Sep 29, 2026 - Abstract #OP-477; Pres time: Oct 19, 2026; 04:45 PM - 06:15 PM; Location: Hall E2; "Starting 24 h later, CDK4/6i abemaciclib (25 or 50 mg/kg) or vehicle control was administered by oral gavage daily for 9 days and tumour size monitored by external callipers... Our investigation demonstrates the value of clonogenic-based drug screens to identify promising drug combinations that warrant clinical evaluation such as CDK4/6i, but also provide opportunities to use drug screens to uncover novel radiobiological resistance mechanisms outside of the typical DNA damage response."
Combination therapy • Genito-urinary Cancer • Prostate Cancer • Solid Tumor • CDK4 • SSTR2
|
|
E. O’Neill 1; F. Amoroso 1; M. Mosley 1; B. Cornelissen 2
|